Wound Dressing Biocompatibility: Intact Skin vs Breached or Compromised Surface

Build a wound-dressing component-to-tissue map

Start with the finished dressing rather than a generic material list. Identify the wound-contact layer, absorbent core, adhesive border, backing film, release liner, gel, foam, alginate, antimicrobial constituent, tubing or connector where applicable. For each component, record whether contact is direct, indirect through fluid or leachables, or absent in normal use.

The map should reflect placement, intended wound type, wear time, replacement frequency and foreseeable migration or leakage. An internal layer can still matter if substances reach the patient through wound exudate or another fluid pathway.

Intact skin versus a breached or compromised surface

FDA's currently published endpoint framework distinguishes surface devices contacting intact skin from surface devices contacting a breached or compromised surface. Because FDA's September 2023 guidance predates ISO 10993-1:2025 and FDA's recognition of the 2025 edition is partial, identify the edition and jurisdictional framework used rather than treating the labels as interchangeable.

Do not assume every wound dressing belongs to the same contact category. The actual design and intended use control the analysis. Likewise, an EU MDR classification under Annex VIII Rule 4 is a separate legal classification question; it is not a substitute for the biological-contact analysis.

Contact duration and repeated exposure

Record both wear per application and cumulative or repeated exposure across the intended treatment. Components may have different durations: an adhesive can contact periwound skin for the full wear time while a released constituent creates another time-dependent pathway. Replacement frequency, overlapping placement and residual adhesive can matter for repeated skin exposure.

FDA's duration categories are planning inputs, not a complete test strategy. Use the actual clinical scenario, including vulnerable populations and compromised tissue, and document assumptions when the labelled maximum and typical use differ.

Plan biological endpoints as questions, not an automatic test battery

Current FDA tables identify biological effects to address for device categories. They do not mean that every effect requires a new test. Existing evidence, material and process knowledge, chemical characterization, toxicological assessment or scientifically justified testing can contribute, depending on the device and question.

• Could a component or released substance cause local cytotoxicity, irritation or sensitization?
• Does breached-surface contact create exposure questions beyond those for an intact-skin adhesive?
• Could formulation ranges, antimicrobial constituents or degradation products change the hazard profile?
• Does repeated use or prolonged wear change exposure or the state of the contacted tissue?
• Which uncertainties require direct evidence, and which are already addressed?

Final-finished and representative test articles

The article should include the actual patient-contacting formulations, adhesive, coating, joining process and sterilization state relevant to the question. Consider formulation ranges, coating weight, absorbency, patient-contacting area, packaging and aging where they could alter the exposure. If a coupon or individual component is used, document how it represents the production device and how cutting or preparation affects exposed surfaces.

For a mixed-contact dressing, one article or extraction may not answer every component-specific question. See the detailed test-article preparation guide before freezing the laboratory protocol.

Keep biological evaluation, sterility, endotoxin and performance separate

Sterility assurance and bacterial-endotoxin control do not replace biological evaluation. Cytotoxicity, sensitization or irritation results do not establish wound-healing performance, absorbency, antimicrobial effectiveness or overall biological safety. Medicinal, antimicrobial, absorbable or animal-derived constituents can also create additional regulatory and evidence questions beyond the scope of this guide.

Under EU MDR, Annex I biological-property requirements and Annex VIII classification rules serve different purposes. A device class conclusion should be made from intended purpose and applicable classification rules, not inferred from an ISO or FDA contact label.

Common wound-dressing documentation failures

1. Assigning one contact category to the complete dressing without mapping components.
2. Ignoring indirect exposure from absorbent cores, gels, adhesives or antimicrobial constituents.
3. Using endpoint tables as automatic testing checklists.
4. Recording one application duration but omitting cumulative or repeated exposure.
5. Testing a material coupon without bridging formulation and processing to the finished dressing.
6. Combining sterility, endotoxin, biocompatibility and wound-healing claims into one conclusion.
7. Equating an EU MDR device class with a biological-contact category.

A qualified biological-safety and regulatory review should resolve the device-specific contact map, endpoint strategy, representative articles and jurisdictional requirements.